27 October 2022 | News
To progress on end-to-end vaccine research and early-stage development including vaccine platform development
Photo Credit: SK bioscience
South Korea's SK bioscience has entered a strategic partnership with Singapore based Hilleman Laboratories to co-develop new vaccine candidates and technology platforms. The MoU signing ceremony was held at Grand Walkerhill Seoul.
The partnership is initiated by signing a Memorandum of Understanding (MoU) to collaborate on end-to-end vaccine research and early-stage development including vaccine platform development, leveraging the development and manufacturing capabilities of both parties.
Hilleman’s vaccine and biologics development and manufacturing hub in Singapore, and SK’s upcoming Research and Process Development (R&PD) Center in Songdo as well as L-HOUSE, its vaccine manufacturing facility in Andong, South Korea will be part of the initative.
Dr Raman Rao, CEO of Hilleman Laboratories, said, “LMICs have historically faced difficulties in vaccine accessibility, with significant economic burden and on health metrics. We collaborate with SK bioscience to support the development of new vaccine platforms to fulfil our mission to accelerate broad access to vaccines for populations in LMICs.”